| |
| |
|
| Insider
Information: |
Gordon Carl L |
| Relationship: |
Director, 10% Owner |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
19 |
|
| Direct
Shares |
5,900 |
|
|
Indirect Shares
|
33,633,839 |
|
|
| Direct
Value |
$9,912 |
|
|
|
Indirect Value
|
$520,209,731 |
|
|
| Total
Shares |
33,639,739 |
|
|
| Total
Value |
$520,219,643 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
5
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
4
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 7.3%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Acadia Pharmaceuticals Inc |
ACAD |
Director |
2004-06-02 |
0 |
2005-04-20 |
1,395,612 |
Premium* |
|
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2005-12-02 |
0 |
2005-12-02 |
1,100,000 |
Premium* |
|
|
Pacira Pharmaceuticals, Inc. |
PCRX |
Director |
|
0 |
2011-02-08 |
2,828,941 |
Premium* |
|
|
Amarin Corp Plc |
AMRN |
Director |
2011-02-28 |
0 |
2012-09-04 |
5,700 |
Premium* |
|
|
Acceleron Pharma Inc |
XLRN |
Director |
|
0 |
2013-09-18 |
8,006 |
Premium* |
|
|
Intellia Therapeutics, Inc. |
NTLA |
Director |
2016-05-11 |
0 |
2016-05-11 |
2,662,180 |
Premium* |
|
|
Selecta Biosciences Inc |
SELB |
Director, 10% Owner |
|
0 |
2016-06-27 |
1,825,415 |
Premium* |
|
|
X4 Pharmaceuticals Inc |
XFOR |
Director, 10% Owner |
2017-11-20 |
0 |
2017-11-20 |
1,868,966 |
Premium* |
|
|
Armo Biosciences Inc |
ARMO |
Director |
2018-01-30 |
0 |
2018-06-22 |
0 |
Premium* |
|
|
Alector, Inc. |
ALEC |
Director, 10% Owner |
2019-02-11 |
0 |
2019-02-11 |
203,200 |
Premium* |
|
|
Turning Point Therapeutics, Inc. |
TPTX |
Director |
2019-04-22 |
0 |
2019-04-22 |
2,027,550 |
Premium* |
|
|
Prevail Therapeutics Inc. |
PRVL |
Director, 10% Owner |
|
0 |
2021-01-22 |
0 |
Premium* |
|
|
Keros Therapeutics, Inc. |
KROS |
Director |
2020-04-13 |
0 |
2020-04-13 |
1,119,812 |
Premium* |
|
|
Oric Pharmaceuticals, Inc. |
ORIC |
Director |
2020-04-24 |
0 |
2021-03-30 |
2,212,571 |
Premium* |
|
|
Adicet Bio, Inc |
ACET |
|
2023-06-01 |
5,900 |
2024-01-25 |
2,930,527 |
Premium* |
|
|
Kinnate Biopharma Inc. |
KNTE |
Director, 10% Owner |
2020-12-07 |
0 |
2024-04-03 |
0 |
Premium* |
|
|
Terns Pharmaceuticals, Inc. |
TERN |
Director, 10% Owner |
2021-02-09 |
0 |
2022-12-23 |
7,619,135 |
Premium* |
|
|
Disc Medicine, Inc |
IRON |
Director, 10% Owner |
|
0 |
2021-02-05 |
5,826,224 |
Premium* |
|
|
Theseus Pharmaceuticals, Inc. |
THRX |
Director, 10% Owner |
2021-10-12 |
0 |
2024-02-14 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KNTE |
Kinnate Biopharma Inc. |
Director |
– • • |
2024-04-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(8,009,729) |
0 |
0 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2024-02-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(17,713,600) |
0 |
0 |
- |
|
| ACET |
Adicet Bio, Inc |
|
– • • |
2024-01-25 |
4 |
B |
$2.40 |
$7,500,000 |
I/I |
3,125,000 |
1,255,985 |
0.01 |
% |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2023-07-17 |
4 |
B |
$3.05 |
$1,463,793 |
I/I |
479,932 |
650,600 |
2.25 |
- |
|
| ACET |
Adicet Bio, Inc |
Director |
– • • |
2023-06-27 |
4 |
B |
$2.09 |
$1,828,750 |
I/I |
875,000 |
748,054 |
2.25 |
% |
|
| ACET |
Adicet Bio, Inc |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,900 |
5,900 |
0 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
Director |
– • • |
2023-05-05 |
4 |
B |
$2.82 |
$2,766,485 |
I/I |
981,023 |
1,368,338 |
2.25 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
Director |
– • • |
2023-05-04 |
4 |
B |
$2.75 |
$1,319,750 |
I/I |
479,909 |
877,827 |
2.25 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
Director |
– • • |
2023-05-02 |
4 |
B |
$2.67 |
$903,160 |
I/I |
338,262 |
794,368 |
2.25 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
Director |
– • • |
2023-05-01 |
4 |
B |
$2.62 |
$1,876,331 |
I/I |
716,157 |
735,542 |
2.25 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
Director |
– • • |
2023-04-28 |
4 |
B |
$2.55 |
$894,410 |
I/I |
350,749 |
610,997 |
2.25 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
Director |
– • • |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,100,000 |
550,000 |
0 |
- |
|
| TERN |
Terns Pharmaceuticals, In... |
Director |
– • • |
2022-12-23 |
4 |
B |
$7.25 |
$1,000,000 |
I/I |
137,931 |
4,882,854 |
2.25 |
% |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-11-07 |
4 |
B |
$5.21 |
$1,000,320 |
I/I |
192,000 |
16,734,518 |
2.25 |
- |
|
| TERN |
Terns Pharmaceuticals, In... |
Director |
– • • |
2022-08-16 |
4 |
B |
$2.42 |
$8,929,800 |
I/I |
3,690,000 |
762,400 |
2.25 |
% |
|
| KNTE |
Kinnate Biopharma Inc. |
Director |
– • – |
2022-02-15 |
4 |
B |
$9.96 |
$89,640 |
I/I |
9,000 |
3,509,030 |
2.1 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
Director |
– • – |
2022-02-14 |
4 |
B |
$9.89 |
$305,486 |
I/I |
30,700 |
3,500,030 |
2.1 |
- |
|
| KNTE |
Kinnate Biopharma Inc. |
Director |
– • – |
2022-02-11 |
4 |
B |
$10.22 |
$1,594,320 |
I/I |
156,000 |
3,469,330 |
2.1 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-01-21 |
4 |
B |
$9.97 |
$1,115,603 |
I/I |
111,896 |
16,542,652 |
2.25 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-01-20 |
4 |
B |
$9.95 |
$348,250 |
I/I |
35,000 |
16,430,756 |
2.25 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-01-19 |
4 |
B |
$9.97 |
$114,864 |
I/I |
11,521 |
16,395,756 |
2.25 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-01-13 |
4 |
B |
$9.43 |
$163,328 |
I/I |
17,320 |
16,384,235 |
2.25 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-01-12 |
4 |
B |
$10.06 |
$190,104 |
I/I |
18,897 |
16,366,915 |
2.25 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
Director |
– • • |
2022-01-11 |
4 |
B |
$9.81 |
$89,319 |
I/I |
8,500 |
16,348,018 |
2.25 |
- |
|
| ACET |
Adicet Bio, Inc |
Director |
– • • |
2021-12-10 |
4 |
A |
$14.00 |
$2,999,990 |
I/I |
214,285 |
242,285 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
